FDA asks Pfizer to conduct RSV vaccine safety study after 2 contract Guillain-Barre syndrome

Two adults over 60 developed Guillain-Barre syndrome after receiving Pfizer’s respiratory syncytial virus vaccine candidate in a phase 3 trial. Now the FDA is asking the pharmaceutical giant to conduct a safety study.